Publication

This paper analyzes the tension between property rights of drug innovators and the public right to accessible medicines. It draws on Thailand's recent decision to issue a compulsory license for a patented heart drug, which was the first time a developing country had used the WTO rules on compulsory licensing outside of the HIV/AIDS area. It further discusses the patent rights of drug companies, the role of manufactures, and the need for access to essential medicines, especially in developing countries.